Evaluating Macrogenics: Insights From 8 Financial Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, 8 analysts have shared their insights on Macrogenics (NASDAQ:MGNX), with opinions ranging from bullish to bearish. The average 12-month price target has dropped by 43.1% to $7.75. Recent analyst actions include several downgrades and lowered price targets, reflecting concerns about the company's financial performance, including a -17.81% decline in revenue growth and challenges in debt management.
August 15, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Macrogenics (NASDAQ:MGNX) has seen a significant drop in its average 12-month price target by 43.1% to $7.75. Recent analyst actions include several downgrades and lowered price targets, reflecting concerns about the company's financial performance, including a -17.81% decline in revenue growth and challenges in debt management.
The significant drop in the average price target and multiple downgrades by analysts indicate a bearish outlook for Macrogenics. The company's financial challenges, including a decline in revenue growth and high debt-to-equity ratio, further support the negative sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100